Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) Study Program

Trial Profile

EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) Study Program

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Empagliflozin (Primary) ; Albiglutide; Alogliptin; Dipeptidyl peptidase 4 inhibitors; Dulaglutide; Exenatide; Glucagon like peptide 1 receptor agonists; Linagliptin; Liraglutide; Lixisenatide; Saxagliptin; Semaglutide; Sitagliptin
  • Indications Cardiovascular disorders; Myocardial infarction; Stroke; Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms EMPRISE; EMPRISE United States
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 13 Jul 2023 Planned End Date changed from 30 Jun 2022 to 31 Dec 2024.
    • 13 Jul 2023 Planned primary completion date changed from 30 Jun 2022 to 31 Dec 2024.
    • 28 Dec 2022 Planned End Date changed from 31 Dec 2022 to 30 Jun 2022.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top